In mCRPC patients with androgen receptor (AR) mutations, treatment with MRT-2359 in combination with enzalutamide led to a 100% PSA response rate ...

In mCRPC patients with androgen receptor (AR) mutations, treatment with MRT-2359 in combination with enzalutamide led to a 100% PSA response rate (5 of 5 patients) and a 100% disease control rate, ...

The G1 certification is the culmination of a multi-month assessment process conducted by IDCA auditors and examiners ...

Data support emergence of differentiating clinical benefit with a favorable safety and tolerability profile for patients with ...

Findings from a phase 1/2 trial (NCT04176) presented at the 2025 American Society of Hematology Annual Meeting and Exposition ...

The MarketWatch News Department was not involved in the creation of this content.-- Median progression-free survival (PFS) in pancreatic neuroendocrine tumor (P-NET) patients was ...

Imviva Biotech, a clinical-stage biotechnology company developing next-generation allogeneic CAR-T cell therapies, today announced that its abstract detailing clinical results ongoing Phase 1/2 trial ...

Avalo Therapeutics (NASDAQ:AVTX) used a presentation at its 46th Annual Healthcare Conference appearance to outline its strategy for AVTX-009, a high-affinity human monoclonal antibody designed to ...

The rate of passing grades among all students in all of the high schools combined improved in every core content area.

Automatic Data Processing is a "Buy" thanks to its impressive Dividend King status and consistent earnings beats. Learn more about ADP's fundamentals.

As regulated industries accelerate AI adoption, Chennareddy’s governed, audit-ready architecture spanning North America, EMEA, and APAC offers a model for compliant enterprise intelligence at scale.

Updated Phase 1 dose-escalation data (n=58) show VIR-5500 monotherapy has a favorable safety profile and was well tolerated with no dose-limiting toxicities observed to date - Dose-dependent anti-tumo ...